ANN ARBOR, Mich., Aug. 9, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will hold its 2nd quarter 2011 investor conference call on Monday, August 15, 2011, at 2:00pm EDT. James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer, will provide an overview of the Company's drug development programs and commercialization efforts of reaZin™ and wellZin™. Julie Caudill, Adeona's Vice President of Finance, will review the Company's financial results for the 2nd quarter ended June 30, 2011.
Adeona will be joined by special guest, Ananda S. Prasad, M.D., Ph.D., a Distinguished Professor of Internal Medicine at Wayne State University School of Medicine, an Adeona Scientific Advisory Board member and the Principal Investigator of two separate clinical studies that evaluated a particular zinc lozenge for reducing symptoms of the common cold. Dr. Prasad will share his expertise in utilizing zinc lozenges to combat symptoms of the common cold and will take questions about his research.
As previously announced, Adeona has obtained exclusive access to Dr. Prasad's statistically significant clinical data that demonstrates a reduction in the duration and severity of symptoms associated with the common cold when at least 75 mg of zinc acetate per day in lozenge form are administered within 24 hours of the onset of symptoms. Based on the reduction of common cold symptoms shown in these two clinical studies, Adeona intends to commercialize an oral zinc lozenge as a homeopathic over-the-counter (OTC) drug under the brand name wellZin™.
Interested parties should call toll free 1-800-860-2442 (U.S.) or 1-866-605-3852 (Canada), or from outside North America +1 412-858-4600, fifteen minutes before the start of the call to register and identify themselves as registrants of the 'Adeona' Conference Call. Any registered caller on the toll free line may ask to be placed in the queue for the Question & Answer session. The call will be simulcast on the web at http://www.videonewswire.com/event.asp?id=81780. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL (http://www.videonewswire.com/event.asp?id=81780) for 30 days after the call.
About Ananda S. Prasad, M.D., Ph.D.
Dr. Prasad recently received the 2010 Mahidol Award in the Field of Public Health for his groundbreaking research. Among his many achievements, he is credited with identifying zinc deficiency as the underlying cause of growth retardation and hypogonadism that has afflicted millions of children in the developing world. Dr. Prasad estimates that over 2 billion people worldwide currently suffer from zinc deficiency. For over five decades, he has been a vocal advocate of zinc supplementation for diseases characterized by zinc deficiency. Dr. Prasad is the 2007 recipient of the American College of Physicians Award for Outstanding Work in Science as Related to Medicine and has over 200 peer-reviewed publications.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products commercially available: reaZin™, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and wellZin™, a homeopathic over-the-counter drug for reducing symptoms associated with the common cold. Adeona also operates a wholly owned clinical reference laboratory, Adeona Clinical Laboratory, that provides a broad array of chemistry and microbiology diagnostic tests. For more information, please visit Adeona's website at www.adeonapharma.com.
This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "could," "potential," "positions," "continue," "expects," "anticipates," "intends," "plans," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the commercialization of wellZin. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of wellZin to achieve desired results, a failure by us to successfully commercialize wellZin and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
SOURCE Adeona Pharmaceuticals, Inc.